Literature DB >> 1918467

Azathioprine in dermatology.

I R Younger1, D W Harris, G B Colver.   

Abstract

Azathioprine has been available for 30 years and is used in a variety of dermatologic conditions. In common with other systemic immunosuppressant drugs, it has potentially serious side effects in both the short and the long term. It has a favorable therapeutic ratio, however, and most side effects can be avoided by administering low doses for short periods. This review describes azathioprine's chemistry, drug interactions, adverse effects, and oncogenicity and then deals with its clinical applications. The well-established uses are discussed first, followed by less conventional ones. In severe, potentially fatal blistering diseases, azathioprine has an undisputed place in management. For intractable, disabling actinic reticuloid and atopic eczema, it has a smaller part to play, and its role is less clear.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1918467     DOI: 10.1016/0190-9622(91)70196-9

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  4 in total

1.  A practical approach to treating autoimmune bullous disorders with systemic medications.

Authors:  Anne Han
Journal:  J Clin Aesthet Dermatol       Date:  2009-05

Review 2.  Azathioprine in dermatology: a review in the light of advances in understanding methylation pharmacogenetics.

Authors:  A Anstey
Journal:  J R Soc Med       Date:  1995-03       Impact factor: 5.344

Review 3.  Management of atopic eczema. Joint Workshop of the British Association of Dermatologists and the Research Unit of the Royal College of Physicians of London.

Authors:  P M McHenry; H C Williams; E A Bingham
Journal:  BMJ       Date:  1995-04-01

4.  Low-dose 6-mercaptopurine in inflammatory bowel disease is associated with minimal hematologic toxicity.

Authors:  C N Bernstein; L Artinian; P A Anton; F Shanahan
Journal:  Dig Dis Sci       Date:  1994-08       Impact factor: 3.199

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.